CompletedNCT00671853
Quetiapine XR or placebo for bipolar depression with generalized anxiety
About this title
Read the official source — NCT00671853Medication studyAges 18–65United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- ClevelandSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- University Hospitals Cleveland Medical Center
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00671853
- Official title
Show the full official title
Quetiapine XR in the Treatment of Comorbid Generalized Anxiety Disorder in Bipolar Depression With or Without Substance Use Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cleveland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Hospitals Cleveland Medical Center, a university.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine XR and Placebo for quetiapine XR.
Who was this study for?
Listed age limits: 18 years to 65 years.
